
During the ACR Convergence 2021 Review Course, Joan Bathon, MD, discussed cardiovascular manifestations of autoimmune diseases, including rheumatoid arthritis.... [Read More]
• By Jason Liebowitz, MD
During the ACR Convergence 2021 Review Course, Joan Bathon, MD, discussed cardiovascular manifestations of autoimmune diseases, including rheumatoid arthritis.... [Read More]
• By Carina Stanton
Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.... [Read More]
• By Susan Bernstein
In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the… [Read More]
• By Kurt Ullman
Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research… [Read More]
• By Marilynn Larkin
NEW YORK (Reuters Health)—Dual energy computed tomography (DECT) can differentiate cardiovascular monosodium urate (MSU) deposits from calcium deposits in patients with gout, potentially identifying those at risk of heart disease, researchers say. Sylvia Strobl, MD, of Medical University Innsbruck and colleagues analyzed calcium scores and MSU deposits in 59 patients with gout (mean age: 59;… [Read More]
• By John Miller
ZURICH (Reuters)—The U.S. Food and Drug Administration (FDA) has rejected Novartis’s bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, according to the Swiss drugmaker. The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those… [Read More]
• By Keri Losavio
“You’re probably going to die tonight. You should call your family.” Jonathan Koch, president and CCO of Asylum Entertainment LLC, told his touching and inspiring story of mysterious illness, resilience and recovery in the keynote presentation of the 2018 ACR/ARHP Annual Meeting.... [Read More]
After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…... [Read More]
• By Gene Emery
(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher… [Read More]
After reviewing a 10-year study, the FDA cautions that prescribing clarithromycin to patients with heart disease increases the risk of heart problems or death…... [Read More]
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.
Visit the official website for the American College of Rheumatology.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.